Seres reports early trial data for SER-155 in cancer therapy side effect
Go back to Seres reports early trial data for SER-155 in cancer therapy side effect| (NASDAQ: MCRB) | Delayed: 4.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.00 | 52 Week High | $44.51 | |||
| Open | $4.00 | 52 Week Low | $8.05 | |||
| Day High | $4.00 | P/E | N/A | |||
| Day Low | $4.00 | EPS | $0.00 | |||
| Volume | 6 | |||||
